HSP90AB1 and idiopathic pulmonary fibrosis: Even though more studies are required, proteomic studies from IPF patients and laboratory analysis of HSP90 inhibitors provide a strong mechanistic rationale for their investigation in IPF, justifying further experimentation in preclinical studies to better identify their anti-fibrotic effects, optimal dose strategy, and potential side effects.